Eupraxia Pharmaceuticals (EPRX) outlined its clinical and commercial strategy for its lead eosinophilic esophagitis (EoE) program at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026. The company's chief executive, James, told H.C. Wainwright equity research analyst Brandon Folkes that durability, compliance and payer positioning are central to the program, rather than a requirement for superior raw efficacy. Eupraxia shares were up 58% over the past year at $8.04, with a market capitalization of $554 million, a valuation InvestingPro described as appearing undervalued.
The company's approach is built around physician-administered delivery during annual endoscopies and the potential for once-a-year dosing. Management said the drug mechanism has already been validated through prior off-label use and referenced the company's DiffuSphere technology. Eupraxia said the single currently approved drug for long-term chronic EoE captures only about 7% to 8% of the market. The company hopes to launch by 2030, by which point EoE is estimated to affect 1 million patients in the United States.
In Phase IIa data, Eupraxia reported a 0% incidence of oropharyngeal candidiasis with its treatment, compared with 25% for Jorveza. The company also reported 0% cortisol suppression, with intact HPA axis function across all tested patients. More than 3,000 individual injections had been completed with zero procedure-related complications. Management said an acceptable oropharyngeal candidiasis rate would be around 2% to 3%.
Phase IIb recruitment was approximately 95% complete. The company expects an interim readout in December that will provide the first placebo-controlled comparison, along with safety, biopsy and symptom data. The interim update is expected to include about 90 patients, or roughly 75% of the trial population, at the 3-month time point; about 45 patients at the 9-month time point; and about 20 to 25 patients at the 1-year time point.
The trial is evaluating a lower dose of 6 mg, or 120 mg total, administered over 52 weeks, or 365 days, and a higher dose of 8 mg, or 160 mg total, over the same period. Management discussed durability of one year for the lower dose and potentially 15 to 18 months for the higher dose. Clinical remission was defined as an improvement of at least 3 points on the Straumann Dysphagia Index. The discussion also referenced the Dysphagia Symptom Questionnaire, Eosinophilic Esophagitis Histology Scoring System, visual esophageal changes and odynophagia. The company said it is aiming for efficacy within plus or minus 10% of DUPIXENT and Eohilia and mentioned the possibility of combining DUPIXENT at a half-dose with Eupraxia's product.
Payer feedback discussed by management varied by treatment duration. At six months, the company said the product would be compelling for severe and non-compliant patients but would not be positioned as a first-line therapy. At nine months, it said the product would move ahead of oral steroids and biologics. At one year, it said the product would be positioned after proton pump inhibitors, clearly ahead of oral steroids for most payers, and clearly ahead of biologics.
Eupraxia said the next 12 to 24 months are decisive for moving toward Phase III and clarifying regulatory pathways. The company also plans proof-of-concept trials in 2027 for benign esophageal strictures and fibrostenosing Crohn's disease. Benign esophageal strictures affect about 1 million U.S. patients, with approximately 500,000 annual balloon endoscopies.
